진행성 또는 전이성 위암 환자에 있어서 Oxaliplatin 투여로 인한 말초신경통증 분석
Oxaliplatin-induced Peripheral Neuropathy in Patients with Advanced or Metastatic Gastric Cancer
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Oxaliplatin is a tolerable and effective drug of choice in the treatment of advanced or metastatic gastric cancer. However, it has many dose-limiting neurotoxicities. This study was performed to assess the incidence and types of oxaliplatin-related neurotoxicities. Sixty-four patients receiving oxaliplatin-involved regimen as salvage therapy on metastatic gastric cancer or as the first-line therapy on advanced gastric cancer were evaluated during the period between September 1, 2006 and February 29, 2008. The patients were treated with oxaliplatin 100 mg/m2 and leucovorin 100 mg/m2 simultaneously as 2-hour-lasting infusion on Day-1 followed by 5-FU 1200 mg/m2 as a 22-hour-lasting continuous infusion both on Day-1 and Day-2 by every other week. We developed questionnaires to evaluate patient-recognized neurotoxic symptoms rather than the observer-described events. Surveys were completed at bedside or via telephone interview. Acute and chronic neurotoxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 3) as well as the Oxaliplatin-specific Neurotoxicity Scale. The Grade-3 neuropathy was reported in 19% of the patients (n=12) and grade-1/2 neuropathy occurred in 70% (n=45). The most common symptom was cold-related dysesthesia (83%) regarded as nociperception by the patients. Some patients (19%) experienced functional impairment affecting activities of daily living such as writing, buttoning, and walking. Even though 74% of the patients (42/57) were prescribed with gabapentin to reduce these peripheral symptoms, it did not appear to derive any benefit from this medication. It is suggested that notify the patients about their oxaliplatin-associated, debilitating symptoms, and educate them any self-care strategy at the initiating phase of the chemotherapy. Moreover, it needs to design the intervention studies regarding the prevention and management of the peripheral neuropathy.
Abstract
Oxaliplatin is a tolerable and effective drug of choice in the treatment of advanced or metastatic gastric cancer. However, it has many dose-limiting neurotoxicities. This study was performed to assess the incidence and types of oxaliplatin-related neurotoxicities. Sixty-four patients receiving oxaliplatin-involved regimen as salvage therapy on metastatic gastric cancer or as the first-line therapy on advanced gastric cancer were evaluated during the period between September 1, 2006 and February 29, 2008. The patients were treated with oxaliplatin 100 mg/m2 and leucovorin 100 mg/m2 simultaneously as 2-hour-lasting infusion on Day-1 followed by 5-FU 1200 mg/m2 as a 22-hour-lasting continuous infusion both on Day-1 and Day-2 by every other week. We developed questionnaires to evaluate patient-recognized neurotoxic symptoms rather than the observer-described events. Surveys were completed at bedside or via telephone interview. Acute and chronic neurotoxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 3) as well as the Oxaliplatin-specific Neurotoxicity Scale. The Grade-3 neuropathy was reported in 19% of the patients (n=12) and grade-1/2 neuropathy occurred in 70% (n=45). The most common symptom was cold-related dysesthesia (83%) regarded as nociperception by the patients. Some patients (19%) experienced functional impairment affecting activities of daily living such as writing, buttoning, and walking. Even though 74% of the patients (42/57) were prescribed with gabapentin to reduce these peripheral symptoms, it did not appear to derive any benefit from this medication. It is suggested that notify the patients about their oxaliplatin-associated, debilitating symptoms, and educate them any self-care strategy at the initiating phase of the chemotherapy. Moreover, it needs to design the intervention studies regarding the prevention and management of the peripheral neuropathy.
참고문헌 (20)
- "2003-2005년 암발생률 및 1993-2005년 발생자의 암생존율"[URL]
- Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~168 (1997)
- Hill ME, "Medical management of advanced gastric cancer", Cancer Treat Rev, 24, pp.113~118 (1998)
- Louvet C, "Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients", J Clin Oncol, pp.4543~4548 (2004)
- Al-Batran SE, "Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer", J Clin Oncol, 22, pp.658~663 (2004)
- Leong T, "Chemotherapy and radiotherapy in the management of gastric cancer", Curr Opin Gastroenterol, 21, pp.633~635 (2005)
- De Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- Wilson RH, "Acute oxaliplatin-induced peripheral nerve hyperexcitability", J Clin Oncol, 20, pp.1767~1774 (2002)
- Cassidy J, "Oxaliplatin-related side effects: characteristics and management", Semin Oncol, 29, pp.11~20 (2002)
- Land SR, "Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07", J Clin Oncol, 25, pp.2205~2211 (2007)
- Gamelin L, "Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway", Clin Cancer Res, 13, pp.6359~6368 (2007)
- Grolleau F, "A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels", J Neurophysiol, 85, pp.2293~2297 (2001)
- Nordlinger B, "Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for respectable liver metastases from colorectal cancer: a randomized controlled trial", Lancet, 371, pp.1007~1016 (2008)
- Mitchell PL, "Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity", Clin Colorectal Cancer, 6, pp.146~151 (2006)
- Grothey A, "Oxaliplatin-safety profile: neurotoxicity", Semin Oncol, 30, pp.5~13 (2003)
- Gamelin L, "Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer", Clin Cancer Res, 10, pp.4055~4061 (2004)
- Petrioli R, "Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin", Cancer Chemother Pharmacol, 61, pp.105~111 (2008)
- Cavanna L, "Oxaliplatin in combination with 5-fluorouracil and leucovorin in patients with metastatic gastric cancer", Am J Clin Oncol, 29, pp.371~375 (2006)
- Leonard G, "Survey of oxaliplatin-associated neurotoxicity using an interviewbased questionnaire in patients with metastatic colorectal cancer", BMC Cancer, 5, pp.116~116 (2005)
- Pietrangeli A, "Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up", Eur Neurol, 56, pp.13~16 (2006)